Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
weekly
|
| gptkbp:approves |
gptkb:FDA
EMA multiple myeloma |
| gptkbp:barrelLength |
IgG1
|
| gptkbp:chemicalFormula |
C6420H9920N1716O1984S44
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 Phase 3 monotherapy NCT03275285 NCT03319667 NCT03374085 in combination therapy |
| gptkbp:debutYear |
2020
|
| gptkbp:developedBy |
Sanofi
|
| gptkbp:drugInterdiction |
immunotherapy
antineoplastic agent |
| https://www.w3.org/2000/01/rdf-schema#label |
Isatuximab
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
gptkb:United_States
|
| gptkbp:mandates |
relapsed or refractory multiple myeloma
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:Japan Europe brand_name_Sarclisa |
| gptkbp:origin |
human
|
| gptkbp:patentStatus |
patented
|
| gptkbp:patentType |
March 2020
|
| gptkbp:productLine |
second line
third line |
| gptkbp:releaseYear |
2010
|
| gptkbp:researchAreas |
ongoing clinical trials
|
| gptkbp:researchFocus |
multiple myeloma treatment
|
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
anemia
thrombocytopenia infusion-related reactions neutropenia |
| gptkbp:targets |
CD38
plasma cells |
| gptkbp:triggerType |
inducing apoptosis
|
| gptkbp:variant |
dexamethasone
pomalidomide |
| gptkbp:weight |
146 kDa
|